Literature DB >> 20940321

Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics.

Kristi E Allen1, Glen J Weiss.   

Abstract

Chemoresistance to many commercially available cancer therapeutic drugs is a common occurrence and contributes to cancer mortality as it often leads to disease progression. There have been a number of studies evaluating the mechanisms of resistance and the biological factors involved. microRNAs have recently been identified as playing a role in the regulation of key genes implicated as cancer therapeutic targets or in mechanisms of chemoresistance including EGFR, MDR1, PTEN, Bak1, and PDCD4 among others. This article briefly reviews chemoresistance mechanisms, discusses how microRNAs can play a role in those mechanisms, and summarizes current research involving microRNAs as both regulators of key target genes for chemoresistance and biomarkers for treatment response. It is clear from the accumulating literature that microRNAs can play an important role in chemoresistance and hold much promise for the development of targeted therapies and personalized medicine. This review brings together much of this new research as a starting point for identifying key areas of interest and potentials for future study. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20940321     DOI: 10.1158/1535-7163.MCT-10-0397

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  71 in total

1.  Phospho-ΔNp63α/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure.

Authors:  Yiping Huang; Alice Y Chuang; Edward A Ratovitski
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

2.  Competing endogenous RNA: A novel posttranscriptional regulatory dimension associated with the progression of cancer.

Authors:  Qingsong Dai; Jixia Li; Keyuan Zhou; Tong Liang
Journal:  Oncol Lett       Date:  2015-09-14       Impact factor: 2.967

3.  A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma.

Authors:  Junegoo Lee; Tilahun Jiffar; Michael E Kupferman
Journal:  PLoS One       Date:  2012-01-20       Impact factor: 3.240

4.  Inhibition of the miR-17-92 Cluster Separates Stages of Palatogenesis.

Authors:  R J Ries; W Yu; N Holton; H Cao; B A Amendt
Journal:  J Dent Res       Date:  2017-06-29       Impact factor: 6.116

5.  Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer.

Authors:  Lyndsay V Rhodes; Syreeta L Tilghman; Stephen M Boue; Shuchun Wang; Hafez Khalili; Shannon E Muir; Melyssa R Bratton; Qiang Zhang; Guangdi Wang; Matthew E Burow; Bridgette M Collins-Burow
Journal:  Oncol Lett       Date:  2011-10-24       Impact factor: 2.967

6.  Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

Authors:  Marta Geretto; Alessandra Pulliero; Camillo Rosano; Dinara Zhabayeva; Rakhmet Bersimbaev; Alberto Izzotti
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

7.  miR-532-5p promotes breast cancer proliferation and migration by targeting RERG.

Authors:  Lei Huang; Xiaoqiao Tang; Xianbiao Shi; Lei Su
Journal:  Exp Ther Med       Date:  2019-11-12       Impact factor: 2.447

8.  Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer.

Authors:  Timothy R Donahue; Andrew H Nguyen; Jennifer Moughan; Luyi Li; Sergei Tatishchev; Paul Toste; James J Farrell
Journal:  J Surg Oncol       Date:  2014-08-17       Impact factor: 3.454

9.  Multimodality therapy for metastatic sarcomas confined to the lung.

Authors:  Russell P Gollard; J Francis Turner
Journal:  Oncol Lett       Date:  2012-07-24       Impact factor: 2.967

10.  Glutathione S-transferases P1 protects breast cancer cell from adriamycin-induced cell death through promoting autophagy.

Authors:  Xiaoliang Dong; Yang Yang; Yi Zhou; Xiaowen Bi; Ningwei Zhao; Zhengping Zhang; Ling Li; Qiyun Hang; Ruhui Zhang; Dan Chen; Peng Cao; Zhimin Yin; Lan Luo
Journal:  Cell Death Differ       Date:  2019-01-25       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.